Motoyuki Matsui
Yamagata University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Motoyuki Matsui.
Circulation-arrhythmia and Electrophysiology | 2011
Yusuke Takagi; Satoshi Yasuda; Ryusuke Tsunoda; Yasuhiro Ogata; Atsushi Seki; Tetsuya Sumiyoshi; Motoyuki Matsui; Toshikazu Goto; Yasuhiko Tanabe; Shozo Sueda; Toshiaki Sato; Satoshi Ogawa; Norifumi Kubo; Shin Ichi Momomura; Hisao Ogawa; Hiroaki Shimokawa
Background—Coronary artery spasm plays an important role in the pathogenesis of ischemic heart disease; however, its role in sudden cardiac death remains to be fully elucidated. We examined the clinical characteristics and outcomes of patients with vasospastic angina (VSA) in our nationwide multicenter registry by the Japanese Coronary Spasm Association. Methods and Results—Between September 2007 and December 2008, 1429 patients with VSA (male/female, 1090/339; median, 66 years) were identified. They were characterized by a high prevalence of smoking and included 35 patients who survived out-of-hospital cardiac arrest (OHCA). The OHCA survivors, as compared with the remaining 1394 non-OHCA patients, were characterized by younger age (median, 58 versus 66 years; P<0.001) and higher incidence of left anterior descending coronary artery spasm (72% versus 53%, P<0.05). In the OHCA survivors, 14 patients underwent implantable cardioverter-defibrillator (ICD) implantation while intensively treated with calcium channel blockers. Survival rate free from major adverse cardiac events was significantly lower in the OHCA survivors compared with the non-OHCA patients (72% versus 92% at 5 years, P<0.001), including appropriate ICD shocks for ventricular fibrillation in 2 patients. Multivariable analysis revealed that OHCA events were significantly correlated with major adverse cardiac events (hazard ratio, 3.25; 95% confidence interval, 1.39 to 7.61; P<0.01). Conclusions—These results from the largest vasospastic angina cohort indicate that vasospasm patients who survived OHCA are high-risk population. Further studies are needed to determine whether implantable cardioverter-defibrillator therapy improves patient prognosis.
European Heart Journal | 2013
Yusuke Takagi; Satoshi Yasuda; Jun Takahashi; Ryusuke Tsunoda; Yasuhiro Ogata; Atsushi Seki; Tetsuya Sumiyoshi; Motoyuki Matsui; Toshikazu Goto; Yasuhiko Tanabe; Shozo Sueda; Toshiaki Sato; Satoshi Ogawa; Norifumi Kubo; Shin-ichi Momomura; Hisao Ogawa; Hiroaki Shimokawa
AIMS Provocation tests of coronary artery spasm are useful for the diagnosis of vasospastic angina (VSA). However, these tests are thought to have a potential risk of arrhythmic complications, including ventricular tachycardia (VT), ventricular fibrillation (VF), and brady-arrhythmias. We aimed to elucidate the safety and the clinical implications of the spasm provocation tests in the nationwide multicentre registry study by the Japanese Coronary Spasm Association. METHODS AND RESULTS A total of 1244 VSA patients (M/F, 938/306; median 66 years) who underwent the spasm provocation tests were enrolled from 47 institutes. The primary endpoint was defined as major adverse cardiac events (MACEs). The provocation tests were performed with either acetylcholine (ACh, 57%) or ergonovine (40%). During the provocation tests, VT/VF and brady-arrhythmias developed at a rate of 3.2 and 2.7%, respectively. Overall incidence of arrhythmic complications was 6.8%, a comparable incidence of those during spontaneous angina attack (7.0%). Multivariable logistic regression analysis demonstrated that diffuse right coronary artery spasm (P < 0.01) and the use of ACh (P < 0.05) had a significant correlation with provocation-related VT/VF. During the median follow-up of 32 months, 69 patients (5.5%) reached the primary endpoint. The multivariable Cox proportional hazard model revealed that mixed (focal plus diffuse) type multivessel spasm had an important association with MACEs (adjusted hazard ratio, 2.84; 95% confidence interval, 1.34-6.03; P < 0.01), whereas provocation-related arrhythmias did not. CONCLUSION The spasm provocation tests have an acceptable level of safety and the evaluation of spasm type may provide useful information for the risk prediction of VSA patients.
Journal of the American College of Cardiology | 2013
Yusuke Takagi; Jun Takahashi; Satoshi Yasuda; Satoshi Miyata; Ryusuke Tsunoda; Yasuhiro Ogata; Atsushi Seki; Tetsuya Sumiyoshi; Motoyuki Matsui; Toshikazu Goto; Yasuhiko Tanabe; Shozo Sueda; Toshiaki Sato; Satoshi Ogawa; Norifumi Kubo; Shin Ichi Momomura; Hisao Ogawa; Hiroaki Shimokawa
OBJECTIVES The present study aimed to develop a comprehensive clinical risk score for vasospastic angina (VSA) patients. BACKGROUND Previous studies demonstrated various prognostic factors of future adverse events in VSA patients. However, to apply these prognostic factors in clinical practice, the assessment of their accumulation in individual patients is important. METHODS The patient database of the multicenter registry study by the Japanese Coronary Spasm Association (JCSA) (n = 1,429; median 66 years; median follow-up 32 months) was utilized for score derivation. RESULTS Multivariable Cox proportional hazard model selected 7 predictors of major adverse cardiac events (MACE). The integer score was assigned to each predictors proportional to their respective adjusted hazard ratio; history of out-of-hospital cardiac arrest (4 points), smoking, angina at rest alone, organic coronary stenosis, multivessel spasm (2 points each), ST-segment elevation during angina, and beta-blocker use (1 point each). According to the total score in individual patients, 3 risk strata were defined; low (score 0 to 2, n = 598), intermediate (score 3 to 5, n = 639) and high (score 6 or more, n = 192). The incidences of MACE in the low-, intermediate-, and high-risk patients were 2.5%, 7.0%, and 13.0%, respectively (p < 0.001). The Cox model for MACE between the 3 risk strata also showed prognostic utility of the scoring system in various clinical subgroups. The average prediction rate of the scoring system in the internal training and validation sets were 86.6% and 86.5%, respectively. CONCLUSIONS We developed a novel scoring system, the JCSA risk score, which may provide the comprehensive risk assessment and prognostic stratification for VSA patients.
Journal of the American College of Cardiology | 2013
Yusuke Takagi; Jun Takahashi; Satoshi Yasuda; Satoshi Miyata; Ryusuke Tsunoda; Yasuhiro Ogata; Atsushi Seki; Tetsuya Sumiyoshi; Motoyuki Matsui; Toshikazu Goto; Yasuhiko Tanabe; Shozo Sueda; Toshiaki Sato; Satoshi Ogawa; Norifumi Kubo; Shin-ichi Momomura; Hisao Ogawa; Hiroaki Shimokawa
OBJECTIVES The present study aimed to develop a comprehensive clinical risk score for vasospastic angina (VSA) patients. BACKGROUND Previous studies demonstrated various prognostic factors of future adverse events in VSA patients. However, to apply these prognostic factors in clinical practice, the assessment of their accumulation in individual patients is important. METHODS The patient database of the multicenter registry study by the Japanese Coronary Spasm Association (JCSA) (n = 1,429; median 66 years; median follow-up 32 months) was utilized for score derivation. RESULTS Multivariable Cox proportional hazard model selected 7 predictors of major adverse cardiac events (MACE). The integer score was assigned to each predictors proportional to their respective adjusted hazard ratio; history of out-of-hospital cardiac arrest (4 points), smoking, angina at rest alone, organic coronary stenosis, multivessel spasm (2 points each), ST-segment elevation during angina, and beta-blocker use (1 point each). According to the total score in individual patients, 3 risk strata were defined; low (score 0 to 2, n = 598), intermediate (score 3 to 5, n = 639) and high (score 6 or more, n = 192). The incidences of MACE in the low-, intermediate-, and high-risk patients were 2.5%, 7.0%, and 13.0%, respectively (p < 0.001). The Cox model for MACE between the 3 risk strata also showed prognostic utility of the scoring system in various clinical subgroups. The average prediction rate of the scoring system in the internal training and validation sets were 86.6% and 86.5%, respectively. CONCLUSIONS We developed a novel scoring system, the JCSA risk score, which may provide the comprehensive risk assessment and prognostic stratification for VSA patients.
European Heart Journal | 2015
Jun Takahashi; Taro Nihei; Yusuke Takagi; Satoshi Miyata; Yuji Odaka; Ryusuke Tsunoda; Atsushi Seki; Tetsuya Sumiyoshi; Motoyuki Matsui; Toshikazu Goto; Yasuhiko Tanabe; Shozo Sueda; Shin Ichi Momomura; Satoshi Yasuda; Hisao Ogawa; Hiroaki Shimokawa
AIMS Although nitrates are widely used as a concomitant therapy with calcium channel blockers (CCBs) for vasospastic angina (VSA), their prognostic contribution remains unclear. The present study aimed to examine the prognostic impact of chronic nitrate therapy in patients with VSA. METHODS AND RESULTS A total of 1429 VSA patients (median 66 years; male/female, 1090/339) were enrolled. The primary endpoint was defined as major adverse cardiac events (MACE). The propensity score matching and multivariable Cox proportional hazard model were used to adjust for selection bias for treatment and potential confounding factors. Among the study patients, 695 (49%) were treated with nitrates, including conventional nitrates [e.g. nitroglycerin (GTN), isosorbide mono- and dinitrate] in 551 and nicorandil in 306. Calcium channel blockers were used in >90% of patients. During the median follow-up period of 32 months, 85 patients (5.9%) reached the primary endpoint. Propensity score-matched analysis demonstrated that the cumulative incidence of MACE was comparable between the patients with and those without nitrates [11 vs. 8% at 5 years; hazard ratio (HR): 1.28; 95% confidence interval (CI): 0.72-2.28, P = 0.40]. Although nicorandil itself had a neutral prognostic effect on VSA (HR: 0.80; 95% CI: 0.28-2.27, P = 0.67), multivariable Cox model revealed the potential harm of concomitant use of conventional nitrates and nicorandil (HR: 2.14; 95% CI: 1.02-4.47; P = 0.044), particularly when GTN and nicorandil were simultaneously administered. CONCLUSIONS Chronic nitrate therapy did not improve the long-term prognosis of VSA patients when combined with CCBs. Furthermore, the VSA patients with multiple nitrates would have increased risk for cardiac events.
Human Genetics | 1994
Toshihiro Tanaka; Ken-ichi Nakahara; Norihiro Kato; Takashi Imai; Tsutomu Yamazaki; Hideshi Tomita; Hiroaki Shimokawa; Hironobu Matsuhashi; Nobuyuki Sato; Motoyuki Matsui; Satoshi Kihira; Akihiko Shimizu; Tetsuya Sano; Noriyuki Haneda; Masaya Kino; Yasushi Miyakita; Rumiko Matsuoka; Ryozo Nagai; Yoshio Yazaki; Yusuke Nakamura
Romano-Ward syndrome (RWS) is an autosomal dominant disorder characterized by prolongation of the electrocardiographic QT interval, with clinical manifestations that include recurrent syncope and sudden death from ventricular arrhythmias. Presymptomatic diagnosis is difficult because of the variability in these signs among carriers, but it is important for clinical management to prevent sudden cardiac death. To find an LQT (long QT) locus in Japanese patients and to identify DNA markers useful for presymptomatic diagnosis, linkage analyses were undertaken in 13 Japanese families with RWS patients by means of two DNA markers located on 11p15.5. One of these marker loci, HRAS, was previously reported to be tightly linked to the LQT locus in another ethnic group. Our analyses of homogeneity suggest evidence for genetic heterogeneity of RWS within the Japanese population.
Journal of Cardiology | 2017
Tetsu Watanabe; Kaoru Ando; Hyuma Daidoji; Yoichiro Otaki; Shigeo Sugawara; Motoyuki Matsui; Eiichiro Ikeno; Osamu Hirono; Hiroshi Miyawaki; Yoshinori Yashiro; Satoshi Nishiyama; Takanori Arimoto; Hiroki Takahashi; Tetsuro Shishido; Takehiko Miyashita; Takuya Miyamoto; Isao Kubota; Cherry study investigators
BACKGROUND There is a residual risk of coronary heart disease (CHD) despite intensive statin therapy for secondary prevention. The aim of this study was to investigate whether coronary plaque regression and stabilization are reinforced by the addition of eicosapentaenoic acid (EPA) to high-dose pitavastatin (PTV). METHODS We enrolled 193 CHD patients who underwent percutaneous coronary intervention (PCI) in six hospitals. Patients were randomly allocated to the PTV group (PTV 4mg/day, n=96) or PTV/EPA group (PTV 4mg/day and EPA 1800mg/day, n=97), and prospectively followed for 6-8 months. Coronary plaque volume and composition in nonstenting lesions were analyzed by integrated backscatter intravascular ultrasound (IB-IVUS). RESULTS The PTV/EPA group showed a greater reduction in total atheroma volume compared to PTV group. IB-IVUS analyses revealed that lipid volume was significantly decreased during follow-up period in only PTV/EPA group. The efficacy of additional EPA therapy on lipid volume reduction was significantly higher in stable angina pectoris (SAP) patients compared to acute coronary syndrome patients. EPA/AA ratio was significantly improved in PTV/EPA group compared to PTV group. There was no significant difference in the incidence of major adverse cardiovascular events and side effects. CONCLUSIONS Combination EPA/PTV therapy significantly reduced coronary plaque volume compared to PTV therapy alone. Plaque stabilization was also reinforced by EPA/PTV therapy in particular SAP patients. The addition of EPA is a promising option to reduce residual CHD risk under intensive statin therapy.
Circulation | 2013
Akiko Kawana; Jun Takahashi; Yusuke Takagi; Satoshi Yasuda; Yasuhiko Sakata; Ryusuke Tsunoda; Yasuhiro Ogata; Atsushi Seki; Tetsuya Sumiyoshi; Motoyuki Matsui; Toshikazu Goto; Yasuhiko Tanabe; Shozo Sueda; Norifumi Kubo; Shin-ichi Momomura; Hisao Ogawa; Hiroaki Shimokawa
Circulation | 1990
Hide Igarashi; Michiyasu Yamaki; Isao Kubota; Kozue Ikeda; Motoyuki Matsui; Kai Tsuiki; Shoji Yasui
Circulation-arrhythmia and Electrophysiology | 2011
Yusuke Takagi; Satoshi Yasuda; Ryusuke Tsunoda; Yasuhiro Ogata; Atsushi Seki; Tetsuya Sumiyoshi; Motoyuki Matsui; Toshikazu Goto; Yasuhiko Tanabe; Shozo Sueda; Toshiaki Sato; Satoshi Ogawa; Norifumi Kubo; Shin-ichi Momomura; Hisao Ogawa; Hiroaki Shimokawa